<DOC>
	<DOCNO>NCT02368912</DOCNO>
	<brief_summary>This study consist four part : Part 1 randomize , double-blind , placebo-controlled , single ascend dose study healthy young male subject evaluate safety , tolerability pharmacokinetics ( PK ) effect certain hormone possible determine high well-tolerated dose ASP1707 healthy young male subject fast condition . Part 2 open label , randomize crossover , single dose study determine effect food pharmacokinetics ASP1707and effect certain hormone healthy young male subject . Part 3 randomized , double-blind , placebo-controlled , multiple ascend dose study evaluate safety , tolerability pharmacokinetics ( PK ) ASP1707 healthy elderly men healthy premenopausal female , determine effect certain hormone male . Age gender also evaluate . Part 4 randomized , double-blind , placebo-controlled , parallel , multiple dose study evaluate safety , tolerability PK ASP1707 , effect certain hormone healthy pre-menopausal female subject .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Effects Single Multiple Ascending Doses ASP1707 Healthy Male Pre-menopausal Female Subjects , Including Comparison Effects Under Fasted Fed Conditions Healthy Young Male Subjects</brief_title>
	<detailed_description>Part 1 comprise 7 dose group 8 healthy young male subject . ASP1707 match placebo ( 3 1 ratio ) give single dose fast condition . The first group receive low dose last group receive high dose . Part 2 ( Food-Effect ) The group consist 12 healthy young male subject receive two separate dos ASP1707 fast fed condition . Half subject dose first fast condition half first FDA high-fat breakfast . Subjects receive alternate treatment second occasion . Dosing separate least 7 day 7 time t1/2 ( terminal elimination half-life ) assess Part 1 . Part 3 Comprises 4 dose group 12 healthy elderly men , two group 12 healthy premenopausal woman . The latter dose ASP1707 placebo parallel 4 male group . Subjects fast fed depend observation Part 2 . Dose level define evaluate interim safety , tolerability PK PD result Part 1 . A low maximum dose use woman men , base preclinical data . Dose escalation men independent dose escalation woman . Women men receive once-daily dosing ; Part 4 include 4 group , 1 placebo 3 ASP1707 , 9 pre-menopausal woman . Subjects dose group receive fix daily dose . Subjects domicile various interval 3 menstrual cycle . Dosing occurs 21 Days subject ' second menstrual cycle study ( Day 1 Period 2 ) ; fast fed depend observation Part 2 .</detailed_description>
	<criteria>Parts 1 &amp; 2 : Healthy young male subject age 18 45 year inclusive Body Mass Index equal 18.5 less 30.0 kg/m2 . Male subject must nonfertile , must practice adequate contraceptive method prevent pregnancy . Part 3 : Healthy elderly male subject age 55 year old , healthy premenopausal female subject age 18 45 inclusive . Body Mass Index equal 18.5 less 30.0 kg/m2 . Male subject must nonfertile , must practice adequate contraceptive method . Female subject must nonchild bear potential , i.e . surgically sterilized practice adequate ( double barrier ) nonhormonal contraceptive method . Part 4 : Healthy premenopausal female subject age 18 45 inclusive . Body Mass Index equal 18.5 less 30.0 kg/m2 . Female subject must nonchild bear potential , i.e . surgically sterilized practice adequate contraceptive method . Females regular menstruation cycle duration 25 30 day . Parts 1 &amp; 2 : Male subject outofrange Testosterone level serum screen . Subjects history cancer . Any liver function test ( i.e . ALT AST ) upper limit normal . A QTc interval &gt; 430 m repeat measurement . Regular use inducer metabolism ( e.g . barbiturate , rifampin ) 3 month prior admission Clinical Unit . Positive serology test HBsAg , anti HAV ( IgM ) , antiHCV antiHIV 1+2 . Part 3 : Pregnancy within 6 month screen assessment breast feed 3 month screen . Male subject outofrange T level serum screen . Positive serology test HBsAg , anti HAV ( IgM ) , antiHCV antiHIV 1+2 . Part 4 : Pregnancy within 6 month screen assessment breast feed 3 month screen . Use hormonal interfering contraceptive 3 month admission ( 3 consecutive menstruation cycle ) OR evidence unovulatory menstrual cycle . Positive serology test HBsAg , anti HAV ( IgM ) , antiHCV antiHIV 1+2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>ASP1707</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Food effect</keyword>
	<keyword>Maximum tolerate dose ( MTD )</keyword>
	<keyword>Healthy subject</keyword>
	<keyword>Single ascend dose</keyword>
	<keyword>Multiple ascend dose</keyword>
</DOC>